Previous Article | Next Article ![]()
Journal of Clinical Microbiology, March 2001, p. 1184-1186, Vol. 39, No. 3
Department of Medical Microbiology, Academic Medical
Center, Amsterdam,1 Diagnostic
Laboratory for Infectious Diseases and Perinatal Screening, National
Institute of Public Health and the Environment,
Bilthoven,2 Department of Medical
Microbiology and Infectious Diseases, Erasmus University Medical
Center, Rotterdam,3 and Departments of
Medical Microbiology and Immunology4 and
Pulmonary Diseases,5 St. Antonius
Hospital, Nieuwegein, The Netherlands
Received 28 September 2000/Returned for modification 7 November
2000/Accepted 3 January 2001
Mycoplasma pneumoniae infection was diagnosed in 18 (12.5%) of 144 adults hospitalized with community-acquired pneumonia. The infection was demonstrated by PCR in 15 patients and by serology, using two methods, in 10 patients. The mean age of the 8 patients with
positive M. pneumoniae PCR and negative serology was
significantly higher than that of the 10 patients with positive serology.
The finding of pathogens causing
community-acquired pneumonia (CAP) depends largely on the patient
specimens provided and the laboratory techniques used. For pathogens
difficult to culture, such as Mycoplasma pneumoniae,
diagnosis relies mainly on serology, requiring paired sera to
demonstrate rises in antibody (3, 13). Rapid diagnosis of
M. pneumoniae infection, however, is essential in order to
make the correct choice of antibiotic regimens for patients with CAP.
Recently, M. pneumoniae PCR on various kinds of respiratory
specimens has been used (1, 7, 15), but it is unclear
which respiratory specimen is most suitable for detection of M. pneumoniae DNA in patients with CAP.
To address this issue, we designed a prospective study among adults
hospitalized with CAP. Results obtained by M. pneumoniae PCR
on various respiratory specimens were compared with results obtained by
serologic testing of paired sera.
Patients and patient specimens.
During a 21-month period
(September 1992 to July 1994), 144 adults admitted to the hospital with
CAP (14), defined according to criteria given by Chow et
al. (5), were enrolled in the study. Informed consent was
obtained from the study participants. From each patient, clinical data,
including gender, age, first day of illness, antibiotic usage, and the
presence of underlying disease, were collected. The median age of the
patients, 93 of whom (65%) were male, was 68 years (range, 20 to 93 years). Underlying disease, such as chronic obstructive pulmonary
disease (COPD), was present in 77 (54%) patients, 4 patients had a
malignancy, and 6 patients were immunocompromised. Of the 59 (41%)
patients who had taken antibiotics prior to enrollment, 38 (65%) used
0095-1137/01/$04.00+0 DOI: 10.1128/JCM.39.3.1184-1186.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Molecular Detection of Mycoplasma
pneumoniae in Adults with Community-Acquired Pneumonia
Requiring Hospitalization
![]()
ABSTRACT
Top
Abstract
Text
References
![]()
TEXT
Top
Abstract
Text
References
-lactam antibiotics, 12 (20%) used macrolides or doxycycline, and 9 (15%) used other antibiotics.
PCR for M. pneumoniae.
Two hundred microliters of
nasopharyngeal and throat swab samples or 1.0 ml of throat wash sample,
bronchial aspirate, or bronchoalveolar lavage specimen was transferred
to a sterile tube and centrifuged at 15,000 × g for 30 min. Sputum samples were suspended in 1.5 ml of 2-SP transport medium.
The suspended samples (100 µl) were transferred to sterile tubes and
centrifuged. Pellets were subjected to DNA extraction according to the
method of Boom et al. (4). DNA extracts were stored at
70°C until processing by PCR was performed. Ten microliters of the
extracted DNA was used as a template in a nested protocol with
P1-gene-specific primers (6).
Serology for M. pneumoniae.
For detection of early
M. pneumoniae-specific antibodies, a microparticle
agglutination (MAG) test (Serodia-MycoII kit; Fujirebio, Tokyo, Japan)
was performed. An immunoglobulin M antibody titer of
1:160 was
regarded as positive. Paired sera were analyzed by the complement
fixation test (CFT). A fourfold rise in titer or a single titer of
1:128 was regarded as positive.
Routine microbiological procedures. Routine procedures included blood culture, Gram staining and culture of sputum, and culture of pleural fluid. CFT on paired sera was performed for respiratory viruses and Coxiella burnetii. For Legionella pneumophila and Chlamydia pneumoniae, commercially available serologic tests were performed. Additionally, respiratory specimens were cultured for C. pneumoniae and processed by C. pneumoniae PCR (14).
Statistics. The Mann-Whitney U test was used to compare the median ages and the median durations of disease at the time of sampling of seropositive and seronegative patients with M. pneumoniae infection as confirmed by PCR.
The etiology of CAP was determined in 93 (65%) of the 144 patients. The most common pathogens were M. pneumoniae (n = 18), Streptococcus pneumoniae (n = 21), Haemophilus influenzae (n = 22), C. pneumoniae (n = 23), and influenza A virus (n = 9), either alone or in combination. In 9 (50%) of the 18 M. pneumoniae-infected patients, at least one other pathogen was detected (Table 1). Lieberman et al. (10) reported identification of at least one other pathogen in addition to M. pneumoniae in 64% of 101 patients hospitalized with CAP. Like in our study, S. pneumoniae and C. pneumoniae were the most frequently diagnosed concomitant pathogens. C. pneumoniae has been reported as a common cause of mixed infections in CAP (11, 14). In our study, three patients with C. pneumoniae had infections concomitant with M. pneumoniae.
|
| |
ACKNOWLEDGMENTS |
|---|
We thank J. Dankert for comments on the manuscript.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Diagnostic Laboratory for Infectious Diseases and Perinatal Screening (LIS), National Institute of Public Health and the Environment, Antonie van Leeuwenhoeklaan 9, P.O. Box 1, 3720 BA Bilthoven, The Netherlands. Phone: 31 30 2743705. Fax: 31 30 2744418.
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Abele-Horn, M.,
U. Busch,
H. Nitschko,
E. Jacobs,
R. Bax,
F. Pfaff,
B. Schaffer, and J. Heesemann.
1998.
Molecular approaches to diagnosis of pulmonary diseases due to Mycoplasma pneumoniae.
J. Clin. Microbiol.
36:548-551 |
| 2. |
Barker, C. E.,
M. Sillis, and T. G. Wreghitt.
1990.
Evaluation of Serodia Myco II particle agglutination test for detecting Mycoplasma pneumoniae antibody: comparison with mu-capture ELISA and indirect immunofluorescence.
J. Clin. Pathol.
43:163-165 |
| 3. |
Bohte, R.,
R. van Furth, and P. J. van den Broek.
1995.
Aetiology of community-acquired pneumonia: a prospective study among adults requiring admission to hospital.
Thorax
50:543-547 |
| 4. |
Boom, R.,
C. J. A. Sol,
M. M. M. Salimans,
C. L. Jansen,
P. M. E. Wertheim-van Dillen, and J. van der Noordaa.
1990.
Rapid and simple method for purification of nucleic acids.
J. Clin. Microbiol.
28:495-503 |
| 5. | Chow, A. W., C. B. Hall, J. O. Klein, R. B. Kammer, R. D. Meyer, and J. S. Remington. 1992. Evaluation of new anti-infective drugs for the treatment of respiratory tract infections. Infectious Diseases Society of America and the Food and Drug Administration. Clin. Infect. Dis. 15(Suppl.1):S62-S88. |
| 6. |
Dorigo-Zetsma, J. W.,
S. A. Zaat,
A. J. Vriesema, and J. Dankert.
1999.
Demonstration by a nested PCR for Mycoplasma pneumoniae that M. pneumoniae load in the throat is higher in patients hospitalised for M. pneumoniae infection than in non-hospitalised subjects.
J. Med. Microbiol.
48:1115-1122 |
| 7. |
Dorigo-Zetsma, J. W.,
S. A. J. Zaat,
P. M. E. Wertheim-van Dillen,
L. Spanjaard,
J. Rijntjes,
G. van Waveren,
J. S. Jensen,
A. F. Angulo, and J. Dankert.
1999.
Comparison of PCR, culture, and serological tests for diagnosis of Mycoplasma pneumoniae respiratory tract infection in children.
J. Clin. Microbiol.
37:14-17 |
| 8. | Ginaldi, L., M. De Martinis, A. D'Ostilio, L. Marini, M. F. Loreto, M. P. Corsi, and D. Quaglino. 1999. The immune system in the elderly. I. Specific humoral immunity. Immunol. Res. 20:101-108[Medline]. |
| 9. | Hauksdottir, G. S., T. Jonsson, V. Sigurdardottir, and A. Love. 1998. Seroepidemiology of Mycoplasma pneumoniae infections in Iceland 1987-96. Scand. J. Infect. Dis. 30:177-180[CrossRef][Medline]. |
| 10. | Lieberman, D., F. Schlaeffer, D. Lieberman, S. Horowitz, O. Horovitz, and A. Porath. 1996. Mycoplasma pneumoniae community-acquired pneumonia: a review of 101 hospitalized adult patients. Respiration 63:261-266[Medline]. |
| 11. | Marrie, T. J., H. Durant, and L. Yates. 1989. Community-acquired pneumonia requiring hospitalization: 5-year prospective study. Rev. Infect. Dis. 11:586-599[Medline]. |
| 12. | Murphy, T. F., and S. Sethi. 1992. Bacterial infection in chronic obstructive pulmonary disease. Am. Rev. Respir. Dis. 146:1067-1083[Medline]. |
| 13. | Socan, M., F. N. Marinic, A. Kraigher, A. Kotnik, and M. Logar. 1999. Microbial aetiology of community-acquired pneumonia in hospitalised patients. Eur. J. Clin. Microbiol. Infect. Dis. 18:777-782[CrossRef][Medline]. |
| 14. |
Verkooyen, R. P.,
D. Willemse,
S. C. A. M. Hiep-van Casteren,
S. A. Mousavi Joulandan,
R. J. Snijder,
J. M. M. van den Bosch,
H. P. T. van Helden,
M. F. Peeters, and H. A. Verbrugh.
1998.
Evaluation of PCR, culture, and serology for diagnosis of Chlamydia pneumoniae respiratory infections.
J. Clin. Microbiol.
36:2301-2307 |
| 15. |
Waris, M. E.,
P. Toikka,
T. Saarinen,
S. Nikkari,
O. Meurman,
R. Vainionpää,
J. Mertsola, and O. Ruuskanen.
1998.
Diagnosis of Mycoplasma pneumoniae pneumonia in children.
J. Clin. Microbiol.
36:3155-3159 |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»